ArticleThe journal of allergy and clinical immunology. In practice2021
Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals.
Article in The journal of allergy and clinical immunology. In practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.The Journal of allergy and clinical immunology · 2022Pooled it
- Clustering of self-reported social and environmental risk factors identifies vulnerable subgroups with increased asthma morbidity.The journal of allergy and clinical immunology. Global · 2026Article
- Respiratory Biologics Utilization, Prescription Predictors, and Outcomes in Patients With Asthma and Comorbid Overweight or Obesity.The journal of allergy and clinical immunology. In practice · 2026Observational
- Population-Level Trends in Asthma Exacerbations After Introduction of Respiratory Biologics.JAMA network open · 2026Article
- Real-world effectiveness of asthma biologics by age of initiation and early-childhood risk factors.Annals of the American Thoracic Society · 2026Article
- Implications of year 1 Trump Administration policies for Americans' lung health.American journal of respiratory and critical care medicine · 2026Article
- Impact of Health Insurance Type on Access to Biologics and Systemic Corticosteroid Exposure in Patients With Severe Asthma: A Real-World Study From the Korean Severe Asthma Registry (KoSAR).Allergy, asthma & immunology research · 2026Article
- Biologic Underutilization and Healthcare Burden in US Patients with Type 2 Severe Asthma.Journal of asthma and allergy · 2026Article
- Expanding Horizons in Severe Asthma: Anti-IgE Biosimilars and the Redefinition of Patient Selection.Allergy, asthma & immunology research · 2026Article
- Health care resource utilization of patients with asthma and food allergy initiating omalizumab.The journal of allergy and clinical immunology. Global · 2025Article
- Trends in Neighborhood Opportunity, Hospitalizations, and Costs for Pediatric Asthma.Pediatric pulmonology · 2025Article
- Race and ethnicity, not just insurance, is associated with biologics initiation in asthma and related conditions.The Journal of allergy and clinical immunology · 2025Article
- Dupilumab Treatment for Aspirin-Exacerbated Respiratory Disease in a Real-World Setting: Impact on Quality of Life and Healthcare Utilization.American journal of rhinology & allergy · 2025Article
- Real-World Biologic Use Patterns in Severe Asthma, 2015-2021: The CLEAR Study.Pragmatic and observational research · 2025Article
- Patients with Higher Exacerbation Burden and Eosinophil Counts are More Likely to Require Multiple Biologics for Asthma Control.Journal of asthma and allergy · 2025Article
- Advancing equity in allergy and immunology: progress, pitfalls, and the path forward.Frontiers in allergy · 2025Review
- Efficacy of Biologics in NSAID-ERD: United Airways From the Nose to the Bronchi.The journal of allergy and clinical immunology. In practice · 2024Review
- RIAIT (Italian Registry of Allergen Immunotherapy): Protocol for a New Tool in a New Vision of Disease-Modifying Therapy for Allergists.Journal of personalized medicine · 2024Article
- Geographic and economic influences on benralizumab prescribing for severe asthma in Japan.Scientific reports · 2024Article
- Health Insurance Type and Outpatient Specialist Care Among Children With Asthma.JAMA network open · 2024Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundDespite bearing a disproportionate burden of poorly controlled asthma, publicly insured individuals are less likely to receive biologics.
objectiveTo assess biologic use by payer among individuals with asthma.
methodsWe used IQVIA's National Disease and Therapeutic Index, a nationally representative, all-payer audit of ambulatory care in the United States, to describe the patterns of use by payer.
resultsAsthma treatment visits in which a biologic product was reported increased from approximately 0.1% of asthma-related visits in 2003 to 1% in 2015 and doubled to 2% by 2019. Omalizumab use initially increased from 2003 to 2006 and plateaued till 2015 when its use declined modestly, coinciding with the release of additional biologic products. In 2019, omalizumab accounted for 37% of biologic treatment visits, mepolizumab 21%, benralizumab 27%, dupilumab 15%, and reslizumab <1%. Biologic treatment visits were higher for privately insured individuals (28.3 per 1000 visits) compared with publicly insured individuals (16.3 per 1000 visits). This difference persisted after accounting for age, sex, and race using nationally representative estimates. White patients accounted for a disproportionate amount of biologic treatment visits among the publicly insured (80%) despite accounting for only 60% of publicly insured asthma treatment visits. No biologic treatment visits were observed for individuals who were uninsured. Half of dupilumab visits were for publicly insured patients, compared with 22% of mepolizumab/benralizumab and 27% of omalizumab visits.
conclusionBiologics were uncommonly used among patients with asthma, and the basis for disproportionately lower use of biologics among the publicly insured, where the burden of uncontrolled asthma is greatest, merits further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.